New Approaches for TB prevention in people living with HIV:
From long-acting injectables to the perfect vaccine

HIV/TB Research Frontiers Meeting in conjunction with CROI 2019

Monday, 4 March 2019, 11:30-13:30
Grand Hyatt Seattle, Leonesa III
721 Pine Street, Seattle, WA 98101, USA

Organized by the World Health Organization

AGENDA

Chairs: Richard Chaisson, Johns Hopkins Medicine, USA
       Diane Havlir, University of California, San Francisco, USA

Conveners: Meg Doherty and Matteo Zignol, WHO, Switzerland

11:30 – 11:35 Introduction and objectives of the meeting

11:35 – 11:55 Long-acting injectables for TB prevention in people living with HIV: prospects and challenges (Nicole Ammerman, Johns Hopkins University Center for TB Research, USA)

11:55 – 12:05 Commentary (Gary Maartens, University of Cape Town, South Africa)

12:05 – 12:35 Discussion

12:35 – 12:55 Recent advances in TB vaccine research: prospects and challenges (Ann Ginsberg, IAVI, USA)

12:55 – 13:05 Commentary (Mark Harrington, Treatment Action Group, USA)

13:05 – 13:25 Discussion

13:25 – 13:30 General conclusion and next steps
**HIV/TB Roadmap at CROI 2019**

**Monday, March 4, 2018**

**WHO Organized CROI-Affiliated events**

**New approaches for TB prevention in people living with HIV:**
*From long acting injectables to the perfect vaccine, Grand Hyatt Seattle, Leonesia III, 11:30-13:30*

This meeting will review the longer-term prospects for TB prevention among people living with HIV and stimulate high level scientific debate on the opportunities, challenges and research implications for developing a more durable and acceptable method of TB prevention.

**Wednesday, March 6, 2018**

**Oral Abstract O-07 TB: From contact to cure and beyond**

10:00 – 12:00, Room 6AB

10:00 77: IPT and pregnancy outcomes in HIV-positive women, the Tshepiso Cohort, Nicole Salazar-Austin

10:15 78: Potential concern for timing of DMPA injection among women treated for HIV and TB, Rosie Mngqibisa

10:30 79: Improving child tuberculosis contact management in Lesotho, Yael Hirsch-Moverman

10:45 80LB: Safety & PK of weekly Rifapentine/Isoniazid (3HP) in adults with HIV on Dolutegravir, Kelly E. Dooley

11:00 81LB: Pharmacokinetics and safety of adjusted Darunavir/Ritonavir with Rifampin in PLWH, Ismaeel Ebrahim

11:15 82: Early bactericidal activity of high-dose Isoniazid against multidrug-resistant TB, Kelly E. Dooley

11:30 83: Long-term mortality after tuberculosis cure in the CIPRA HT-001 Trial, Yvetot Joseph

11:45 84LB: QT effects of Bedaquiline, Delamanid or both in MDR-TB patients: The Deliberate Trial, Gary Maartens

**Symposium S-5 Coinfections: Tuberculosis, Hepatitis B and C, and HIV, 16:00 - 18:00, Room 6E**

17:00 114: Choices and dilemmas: Preventing tuberculosis in people with HIV infection, Amita Gupta

17:30 115: Treating multidrug-resistant tuberculosis in the real world: new drugs and regimens, Jennifer Furin

**Poster Sessions (poster numbers in brackets)**

**Tuesday March 5, 14:30-16:00**

**Poster Hall 4EF**

Poster P-C1: AIDS malignancies: Karposi Sarcoma and KSHV (268)

**Wednesday March 6, 14:30-16:00**

**Poster Hall 4EF**

Poster P-O3: Novel diagnostics for latent and active TB (714-719LB)
Poster P-O4: TB screening and preventive therapy (720-724)
Poster P-O5: The intersection of HIV and TB (725-736)
Poster P-O6: Drug-resistant TB (738-742)

**Thursday March 7, 14:30-16:00**

**Poster Hall 4EF**

Poster P-P3: Pharmacokinetics in pregnancy and postpartum (759)
Poster P-Q7: Antiretroviral pharmacokinetics, safety, & efficacy in children and youth (825)
Poster P-V1: Art Initiation (1021)